用MAGIC算法概率 (MAP) 引导的急性移植与宿主疾病的预防性治疗:一种随机对照试验
Qiang Zeng1, Hang Zhang1, Pu Kuang1
1Department of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, China.
American journal of hematology
|July 27, 2023
概括
以MAGIC算法概率 (MAP) 为指导的预防性甲基普雷迪尼索隆治疗,在干细胞移植后显著减少了急性移植对宿主疾病 (aGvHD). 这种方法显示出对管理aGvHD的希望,而不会增加感染或非复发性死亡率.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 移植医学 移植医学
背景情况:
- 急性移植对宿主疾病 (aGvHD) 是全源造血干细胞移植 (allo-HSCT) 后的一种主要并发症,对非复发性死亡率 (NRM) 作出重大贡献.
- MAGIC算法概率 (MAP) 已经成为一种工具,可以根据患者患aGvHD的风险对患者进行分层.
研究的目的:
- 评估预防性甲基普雷迪尼索隆治疗aGvHD的疗效,在被MAP确定为中等或高风险的患者中.
- 评估这种预防策略对非复发死亡率,感染和其他并发症的影响.
主要方法:
- 用ST2和Reg3α水平计算了MAP,用于HSCT后的第7,14,21和28天.
- 中期和高风险患者被随机分配给接受预防性甲基前尼索隆或不接受治疗 (对照).
- 包括aGvHD发病率,NRM,感染和细胞大脑病毒 (CMV) 反激活在内的结果在各组之间进行了比较.
主要成果:
- 与对照组相比,甲基普雷迪尼索隆组的2级+和3级+aGvHD发病率明显较低 (分别为35.5%与66.7%和12.9%与42.9%).
- 甲基prednisolone组的aGvHD发病率与低风险组相似.
- 在6个月后的NRM或甲基普雷迪尼索隆和对照组之间的感染率中没有发现显著差异.
结论:
- 以MAP为指导的预防性甲基prednisolone治疗是一种有前途的策略,用于减少allo-HSCT后aGvHD的发病率.
- 在短期内,这种治疗方法在NRM和感染率方面似乎是安全的.
- 需要进一步研究以确定这种干预措施的长期疗效和安全性.
更多相关视频
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
14.6K
06:06Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
Published on: May 23, 2019
7.2K
相关概念视频
Bone Marrow Sampling and Transplants
360
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
360
Cell-mediated Immune Responses
68.9K
Overview
68.9K
